Leutipol

Imatinib, the active ingredient in Leutipol, is a tyrosine kinase inhibitor presented as an oral tablet for oral use. It is employed in the treatment of certain blood cancers and tumors, including chronic myeloid leukemia, Philadelphia‑positive acute lymphoblastic leukemia, gastrointestinal stromal tumor, and dermatofibrosarcoma protuberans.

GNH USA supplies Leutipol as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide across multiple regulatory jurisdictions.

Imatinib targets malignant cells driven by specific tyrosine‑kinase pathways.

- Chronic myeloid leukemia: reduces abnormal white‑blood‑cell proliferation and improves survival. - Philadelphia‑positive acute lymphoblastic leukemia: induces remission by blocking BCR‑ABL signaling. - Gastrointestinal stromal tumor: inhibits KIT‑driven tumor growth and delays disease progression. - Dermatofibrosarcoma protuberans: suppresses PDGFR‑mediated tumor cell proliferation.

Imatinib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Diarrhea: loose stools. - Edema: swelling of hands, feet or face. - Fatigue: general tiredness. - Muscle cramps: occasional painful muscle contractions. - Rash: skin